A Phase I clinical trial to investigate the safety and tolerability of NK105 when co-administered with carboplatin once per week to Japanese patients with advanced solid cancers.
Phase of Trial: Phase I
Latest Information Update: 10 Feb 2017
At a glance
- Drugs NK 105 (Primary) ; Carboplatin
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Nippon Kayaku
- 09 Feb 2017 Status changed from recruiting to discontinued.
- 14 Jun 2016 New trial record